These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas. Zhao F; Cui Y; Li M; Fu Z; Chen Z; Kong L; Yang G; Yu J Nucl Med Biol; 2014 Sep; 41(8):710-5. PubMed ID: 24929963 [TBL] [Abstract][Full Text] [Related]
5. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. Troost EG; Bussink J; Hoffmann AL; Boerman OC; Oyen WJ; Kaanders JH J Nucl Med; 2010 Jun; 51(6):866-74. PubMed ID: 20484426 [TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET. Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872 [TBL] [Abstract][Full Text] [Related]
7. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma. Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650 [TBL] [Abstract][Full Text] [Related]
8. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557 [TBL] [Abstract][Full Text] [Related]
9. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944 [TBL] [Abstract][Full Text] [Related]
10. Repeatability of Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473 [TBL] [Abstract][Full Text] [Related]
11. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Hatakeyama T; Kawai N; Nishiyama Y; Yamamoto Y; Sasakawa Y; Ichikawa T; Tamiya T Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2009-17. PubMed ID: 18542957 [TBL] [Abstract][Full Text] [Related]
12. FLT-PET in previously untreated patients with low-grade glioma can predict their overall survival. Belohlavek O; Fencl P; Majovsky M; Jaruskova M; Benes V Nucl Med Rev Cent East Eur; 2014; 17(1):7-12. PubMed ID: 24610646 [TBL] [Abstract][Full Text] [Related]
13. Combining 3'-Deoxy-3'-[18F] fluorothymidine and MRI increases the sensitivity of glioma volume detection. Fernandez P; Zanotti-Fregonara P; Eimer S; Gimbert E; Monteil P; Penchet G; Lamare F; Perez P; Vimont D; Ledure S; Tourdias T; Loiseau H Nucl Med Commun; 2019 Oct; 40(10):1066-1071. PubMed ID: 31469809 [TBL] [Abstract][Full Text] [Related]
14. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer. Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733 [TBL] [Abstract][Full Text] [Related]
15. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166 [TBL] [Abstract][Full Text] [Related]
16. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318 [TBL] [Abstract][Full Text] [Related]
17. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Jeong SY; Lim SM Nucl Med Biol; 2012 Oct; 39(7):977-81. PubMed ID: 22483845 [TBL] [Abstract][Full Text] [Related]
18. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607 [TBL] [Abstract][Full Text] [Related]
19. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896 [TBL] [Abstract][Full Text] [Related]
20. Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Backes H; Ullrich R; Neumaier B; Kracht L; Wienhard K; Jacobs AH Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1960-7. PubMed ID: 19672593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]